Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1520

1.

Coumarins from Magydaris pastinacea as inhibitors of the tumour-associated carbonic anhydrases IX and XII: isolation, biological studies and in silico evaluation.

Fois B, Distinto S, Meleddu R, Deplano S, Maccioni E, Floris C, Rosa A, Nieddu M, Caboni P, Sissi C, Angeli A, Supuran CT, Cottiglia F.

J Enzyme Inhib Med Chem. 2020 Dec;35(1):539-548. doi: 10.1080/14756366.2020.1713114.

PMID:
31948300
2.

Sulfocoumarins as dual inhibitors of human carbonic anhydrase isoforms IX/XII and of human thioredoxin reductase.

Krasavin M, Žalubovskis R, Grandāne A, Domračeva I, Zhmurov P, Supuran CT.

J Enzyme Inhib Med Chem. 2020 Dec;35(1):506-510. doi: 10.1080/14756366.2020.1712596.

PMID:
31928252
3.

Crystal structure and chemical inhibition of essential schistosome host-interactive virulence factor carbonic anhydrase SmCA.

Da'dara AA, Angeli A, Ferraroni M, Supuran CT, Skelly PJ.

Commun Biol. 2019 Sep 5;2(1):333. doi: 10.1038/s42003-019-0578-0.

PMID:
31925135
4.

Benzimidazole derivatives as potent and isoform selective tumor-associated carbonic anhydrase IX/XII inhibitors.

Uslu AG, Gür Maz T, Nocentini A, Banoglu E, Supuran CT, Çalışkan B.

Bioorg Chem. 2019 Dec 28;95:103544. doi: 10.1016/j.bioorg.2019.103544. [Epub ahead of print]

PMID:
31915112
5.

Synthesis and human carbonic anhydrase I, II, VA, and XII inhibition with novel amino acid-sulphonamide conjugates.

Küçükbay H, Buğday N, Küçükbay FZ, Ageli A, Bartolucci G, Supuran CT.

J Enzyme Inhib Med Chem. 2020 Dec;35(1):489-497. doi: 10.1080/14756366.2019.1710503.

PMID:
31914827
6.

Pyrrolo and pyrrolopyrimidine sulfonamides act as cytotoxic agents in hypoxia via inhibition of transmembrane carbonic anhydrases.

Khalil OM, Kamal AM, Bua S, El Sayed Teba H, Nissan YM, Supuran CT.

Eur J Med Chem. 2019 Dec 30;188:112021. doi: 10.1016/j.ejmech.2019.112021. [Epub ahead of print]

PMID:
31901743
7.

Sulphonamides incorporating 1,3,5-triazine structural motifs show antioxidant, acetylcholinesterase, butyrylcholinesterase, and tyrosinase inhibitory profile.

Lolak N, Boga M, Tuneg M, Karakoc G, Akocak S, Supuran CT.

J Enzyme Inhib Med Chem. 2020 Dec;35(1):424-431. doi: 10.1080/14756366.2019.1707196.

PMID:
31899985
8.

Synthesis and selective inhibitory effects of some 2-oxindole benzenesulfonamide conjugates on human carbonic anhydrase isoforms CA I, CA II, CA IX and CAXII.

George RF, Said MF, Bua S, Supuran CT.

Bioorg Chem. 2019 Dec 23;95:103514. doi: 10.1016/j.bioorg.2019.103514. [Epub ahead of print]

PMID:
31887473
9.

A potentiated cooperation of carbonic anhydrase IX and histone deacetylase inhibitors against cancer.

Ruzzolini J, Laurenzana A, Andreucci E, Peppicelli S, Bianchini F, Carta F, Supuran CT, Romanelli MN, Nediani C, Calorini L.

J Enzyme Inhib Med Chem. 2020 Dec;35(1):391-397. doi: 10.1080/14756366.2019.1706090.

PMID:
31865754
10.

Inhibition survey with phenolic compounds against the δ- and η-class carbonic anhydrases from the marine diatom thalassiosira weissflogii and protozoan Plasmodium falciparum.

Alissa SA, Alghulikah HA, ALOthman ZA, Osman SM, Del Prete S, Capasso C, Nocentini A, Supuran CT.

J Enzyme Inhib Med Chem. 2020 Dec;35(1):377-382. doi: 10.1080/14756366.2019.1706089.

PMID:
31856608
11.

Development of a cheminformatics platform for selectivity analyses of carbonic anhydrase inhibitors.

Poli G, Galati S, Martinelli A, Supuran CT, Tuccinardi T.

J Enzyme Inhib Med Chem. 2020 Dec;35(1):365-371. doi: 10.1080/14756366.2019.1705291.

PMID:
31854205
12.

Novel sulphonamides incorporating triazene moieties show powerful carbonic anhydrase I and II inhibitory properties.

Bilginer S, Gonder B, Gul HI, Kaya R, Gulcin I, Anil B, Supuran CT.

J Enzyme Inhib Med Chem. 2020 Dec;35(1):325-329. doi: 10.1080/14756366.2019.1700240.

13.

Novel benzofuran-based sulphonamides as selective carbonic anhydrases IX and XII inhibitors: synthesis and in vitro biological evaluation.

Abdelrahman MA, Eldehna WM, Nocentini A, Ibrahim HS, Almahli H, Abdel-Aziz HA, Abou-Seri SM, Supuran CT.

J Enzyme Inhib Med Chem. 2020 Dec;35(1):298-305. doi: 10.1080/14756366.2019.1697250.

14.

Screening of benzenesulfonamide in combination with chemically diverse fragments against carbonic anhydrase by differential scanning fluorimetry.

Krasavin M, Kalinin S, Zozulya S, Gryniukova A, Borysko P, Angeli A, Supuran CT.

J Enzyme Inhib Med Chem. 2020 Dec;35(1):306-310. doi: 10.1080/14756366.2019.1698562.

15.

Design, synthesis and molecular modelling studies of some pyrazole derivatives as carbonic anhydrase inhibitors.

Dizdaroglu Y, Albay C, Arslan T, Ece A, Turkoglu EA, Efe A, Senturk M, Supuran CT, Ekinci D.

J Enzyme Inhib Med Chem. 2020 Dec;35(1):289-297. doi: 10.1080/14756366.2019.1695791.

16.

"A Sweet Combination": Developing Saccharin and Acesulfame K Structures for Selectively Targeting the Tumor-Associated Carbonic Anhydrases IX and XII.

Bua S, Lomelino C, Murray AB, Osman SM, ALOthman ZA, Bozdag M, Abdel-Aziz HA, Eldehna WM, McKenna R, Nocentini A, Supuran CT.

J Med Chem. 2020 Jan 9;63(1):321-333. doi: 10.1021/acs.jmedchem.9b01669. Epub 2019 Dec 18.

PMID:
31794211
17.

Plasmatic exosomes from prostate cancer patients show increased carbonic anhydrase IX expression and activity and low pH.

Logozzi M, Mizzoni D, Capasso C, Del Prete S, Di Raimo R, Falchi M, Angelini DF, Sciarra A, Maggi M, Supuran CT, Fais S.

J Enzyme Inhib Med Chem. 2020 Dec;35(1):280-288. doi: 10.1080/14756366.2019.1697249.

18.

Aryl derivatives of 3H-1,2-benzoxathiepine 2,2-dioxide as carbonic anhydrase inhibitors.

Pustenko A, Nocentini A, Balašova A, Alafeefy A, Krasavin M, Žalubovskis R, Supuran CT.

J Enzyme Inhib Med Chem. 2020 Dec;35(1):245-254. doi: 10.1080/14756366.2019.1695795.

19.

Benzothiazole derivatives as anticancer agents.

Irfan A, Batool F, Zahra Naqvi SA, Islam A, Osman SM, Nocentini A, Alissa SA, Supuran CT.

J Enzyme Inhib Med Chem. 2020 Dec;35(1):265-279. doi: 10.1080/14756366.2019.1698036. Review.

20.

Carbonic anhydrase IX as a novel candidate in liquid biopsy.

Ozensoy Guler O, Supuran CT, Capasso C.

J Enzyme Inhib Med Chem. 2020 Dec;35(1):255-260. doi: 10.1080/14756366.2019.1697251. Review.

21.

Sulfonamide/sulfamate switch with a series of piperazinylureido derivatives: Synthesis, kinetic and in silico evaluation as carbonic anhydrase isoforms I, II, IV, and IX inhibitors.

Nocentini A, Moi D, Deplano A, Osman SM, AlOthman ZA, Balboni G, Supuran CT, Onnis V.

Eur J Med Chem. 2020 Jan 15;186:111896. doi: 10.1016/j.ejmech.2019.111896. Epub 2019 Nov 21.

PMID:
31784185
22.

Further validation of strecker-type α-aminonitriles as a new class of potent human carbonic anhydrase II inhibitors: hit expansion within the public domain using differential scanning fluorimetry leads to chemotype refinement.

Krasavin M, Kalinin S, Zozulya S, Griniukova A, Borysko P, Angeli A, Supuran CT.

J Enzyme Inhib Med Chem. 2020 Dec;35(1):165-171. doi: 10.1080/14756366.2019.1693556.

23.

Synthesis, biological and molecular dynamics investigations with a series of triazolopyrimidine/triazole-based benzenesulfonamides as novel carbonic anhydrase inhibitors.

Said MA, Eldehna WM, Nocentini A, Bonardi A, Fahim SH, Bua S, Soliman DH, Abdel-Aziz HA, Gratteri P, Abou-Seri SM, Supuran CT.

Eur J Med Chem. 2020 Jan 1;185:111843. doi: 10.1016/j.ejmech.2019.111843. Epub 2019 Nov 2.

PMID:
31718943
24.

Direct and straightforward access to substituted alkyl selenols as novel carbonic anhydrase inhibitors.

Tanini D, Capperucci A, Ferraroni M, Carta F, Angeli A, Supuran CT.

Eur J Med Chem. 2020 Jan 1;185:111811. doi: 10.1016/j.ejmech.2019.111811. Epub 2019 Oct 30.

PMID:
31693947
25.

Bioisosteric Development of Multitarget Nonsteroidal Anti-Inflammatory Drug-Carbonic Anhydrases Inhibitor Hybrids for the Management of Rheumatoid Arthritis.

Bua S, Lucarini L, Micheli L, Menicatti M, Bartolucci G, Selleri S, Di Cesare Mannelli L, Ghelardini C, Masini E, Carta F, Gratteri P, Nocentini A, Supuran CT.

J Med Chem. 2019 Nov 15. doi: 10.1021/acs.jmedchem.9b01130. [Epub ahead of print]

PMID:
31689108
26.

Design, synthesis, in vitro inhibition and toxicological evaluation of human carbonic anhydrases I, II and IX inhibitors in 5-nitroimidazole series.

Aspatwar A, Parvathaneni NK, Barker H, Anduran E, Supuran CT, Dubois L, Lambin P, Parkkila S, Winum JY.

J Enzyme Inhib Med Chem. 2020 Dec;35(1):109-117. doi: 10.1080/14756366.2019.1685510.

27.

Biochemical and Structural Insights into Carbonic Anhydrase XII/Fab6A10 Complex.

Alterio V, Kellner M, Esposito D, Liesche-Starnecker F, Bua S, Supuran CT, Monti SM, Zeidler R, De Simone G.

J Mol Biol. 2019 Dec 6;431(24):4910-4921. doi: 10.1016/j.jmb.2019.10.022. Epub 2019 Nov 1.

PMID:
31682835
28.

Why hasn't there been more progress in new Chagas disease drug discovery?

Vermelho AB, Rodrigues GC, Supuran CT.

Expert Opin Drug Discov. 2019 Oct 31:1-14. doi: 10.1080/17460441.2020.1681394. [Epub ahead of print]

PMID:
31670987
29.

In vitro inhibition of Mycobacterium tuberculosis β-carbonic anhydrase 3 with Mono- and dithiocarbamates and evaluation of their toxicity using zebrafish developing embryos.

Aspatwar A, Hammaren M, Parikka M, Parkkila S, Carta F, Bozdag M, Vullo D, Supuran CT.

J Enzyme Inhib Med Chem. 2020 Dec;35(1):65-71. doi: 10.1080/14756366.2019.1683007.

30.

Phosphonamidates are the first phosphorus-based zinc binding motif to show inhibition of β-class carbonic anhydrases from bacteria, fungi, and protozoa.

Alissa SA, Alghulikah HA, Alothman ZA, Osman SM, Del Prete S, Capasso C, Nocentini A, Supuran CT.

J Enzyme Inhib Med Chem. 2020 Dec;35(1):59-64. doi: 10.1080/14756366.2019.1681987.

31.

Multivalent Carbonic Anhydrases Inhibitors.

Carta F, Dumy P, Supuran CT, Winum JY.

Int J Mol Sci. 2019 Oct 28;20(21). pii: E5352. doi: 10.3390/ijms20215352. Review.

32.

3-Hydrazinoisatin-based benzenesulfonamides as novel carbonic anhydrase inhibitors endowed with anticancer activity: Synthesis, in vitro biological evaluation and in silico insights.

Abo-Ashour MF, Eldehna WM, Nocentini A, Bonardi A, Bua S, Ibrahim HS, Elaasser MM, Kryštof V, Jorda R, Gratteri P, Abou-Seri SM, Supuran CT.

Eur J Med Chem. 2019 Dec 15;184:111768. doi: 10.1016/j.ejmech.2019.111768. Epub 2019 Oct 8.

PMID:
31629164
33.

Mycobacterium tuberculosis β-Carbonic Anhydrases: Novel Targets for Developing Antituberculosis Drugs.

Aspatwar A, Kairys V, Rala S, Parikka M, Bozdag M, Carta F, Supuran CT, Parkkila S.

Int J Mol Sci. 2019 Oct 17;20(20). pii: E5153. doi: 10.3390/ijms20205153. Review.

34.

A structure-based approach towards the identification of novel antichagasic compounds: Trypanosoma cruzi carbonic anhydrase inhibitors.

Llanos MA, Sbaraglini ML, Villalba ML, Ruiz MD, Carrillo C, Alba Soto C, Talevi A, Angeli A, Parkkila S, Supuran CT, Gavernet L.

J Enzyme Inhib Med Chem. 2020 Dec;35(1):21-30. doi: 10.1080/14756366.2019.1677638.

35.

Extending the γ-class carbonic anhydrases inhibition profiles with phenolic compounds.

Nocentini A, Osman SM, Del Prete S, Capasso C, ALOthman ZA, Supuran CT.

Bioorg Chem. 2019 Dec;93:103336. doi: 10.1016/j.bioorg.2019.103336. Epub 2019 Oct 3.

PMID:
31604186
36.

Personalized Treatment Response Assessment for Rare Childhood Tumors Using Microcalorimetry-Exemplified by Use of Carbonic Anhydrase IX and Aquaporin 1 Inhibitors.

Gros SJ, Holland-Cunz SG, Supuran CT, Braissant O.

Int J Mol Sci. 2019 Oct 9;20(20). pii: E4984. doi: 10.3390/ijms20204984.

37.

Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019.

Supuran CT, Altamimi ASA, Carta F.

Expert Opin Ther Pat. 2019 Oct;29(10):781-792. doi: 10.1080/13543776.2019.1679117. Epub 2019 Oct 15. Review.

PMID:
31596641
38.

Extending the Inhibition Profiles of Coumarin-Based Compounds Against Human Carbonic Anhydrases: Synthesis, Biological, and In Silico Evaluation.

Kartsev V, Geronikaki A, Bua S, Nocentini A, Petrou A, Lichitsky B, Frasinyuk M, Leitans J, Kazaks A, Tars K, Supuran CT.

Molecules. 2019 Oct 4;24(19). pii: E3580. doi: 10.3390/molecules24193580.

39.

Pseudomonas aeruginosa β-carbonic anhydrase, psCA1, is required for calcium deposition and contributes to virulence.

Lotlikar SR, Kayastha BB, Vullo D, Khanam SS, Braga RE, Murray AB, McKenna R, Supuran CT, Patrauchan MA.

Cell Calcium. 2019 Dec;84:102080. doi: 10.1016/j.ceca.2019.102080. Epub 2019 Sep 27.

PMID:
31589941
40.

Synthesis, cytotoxicities, and carbonic anhydrase inhibition potential of 6-(3-aryl-2-propenoyl)-2(3H)-benzoxazolones.

Bilginer S, Gul HI, Erdal FS, Sakagami H, Levent S, Gulcin I, Supuran CT.

J Enzyme Inhib Med Chem. 2019 Dec;34(1):1722-1729. doi: 10.1080/14756366.2019.1670657.

41.

Rho-kinase inhibitors in the management of glaucoma.

Berrino E, Supuran CT.

Expert Opin Ther Pat. 2019 Oct;29(10):817-827. doi: 10.1080/13543776.2019.1670812. Epub 2019 Oct 1. Review.

PMID:
31573364
42.

The management of glaucoma and macular degeneration.

Supuran CT.

Expert Opin Ther Pat. 2019 Oct;29(10):745-747. doi: 10.1080/13543776.2019.1674285. No abstract available.

PMID:
31566015
43.

A New Kid on the Block? Carbonic Anhydrases as Possible New Targets in Alzheimer's Disease.

Provensi G, Carta F, Nocentini A, Supuran CT, Casamenti F, Passani MB, Fossati S.

Int J Mol Sci. 2019 Sep 24;20(19). pii: E4724. doi: 10.3390/ijms20194724. Review.

44.

Synthesis of coumarin-sulfonamide derivatives and determination of their cytotoxicity, carbonic anhydrase inhibitory and molecular docking studies.

Zengin Kurt B, Sonmez F, Ozturk D, Akdemir A, Angeli A, Supuran CT.

Eur J Med Chem. 2019 Dec 1;183:111702. doi: 10.1016/j.ejmech.2019.111702. Epub 2019 Sep 14.

PMID:
31542715
45.

Agents for the prevention and treatment of age-related macular degeneration and macular edema: a literature and patent review.

Supuran CT.

Expert Opin Ther Pat. 2019 Oct;29(10):761-767. doi: 10.1080/13543776.2019.1671353. Epub 2019 Sep 24. Review.

PMID:
31540558
46.

Continued exploration and tail approach synthesis of benzenesulfonamides containing triazole and dual triazole moieties as carbonic anhydrase I, II, IV and IX inhibitors.

Vats L, Kumar R, Bua S, Nocentini A, Gratteri P, Supuran CT, Sharma PK.

Eur J Med Chem. 2019 Dec 1;183:111698. doi: 10.1016/j.ejmech.2019.111698. Epub 2019 Sep 12.

PMID:
31539777
47.

Novel 2-substituted-benzimidazole-6-sulfonamides as carbonic anhydrase inhibitors: synthesis, biological evaluation against isoforms I, II, IX and XII and molecular docking studies.

Milite C, Amendola G, Nocentini A, Bua S, Cipriano A, Barresi E, Feoli A, Novellino E, Da Settimo F, Supuran CT, Castellano S, Cosconati S, Taliani S.

J Enzyme Inhib Med Chem. 2019 Dec;34(1):1697-1710. doi: 10.1080/14756366.2019.1666836.

48.

Anti-Helicobacter pylori activity of ethoxzolamide.

Modak JK, Tikhomirova A, Gorrell RJ, Rahman MM, Kotsanas D, Korman TM, Garcia-Bustos J, Kwok T, Ferrero RL, Supuran CT, Roujeinikova A.

J Enzyme Inhib Med Chem. 2019 Dec;34(1):1660-1667. doi: 10.1080/14756366.2019.1663416.

49.

Activation of α-, β-, γ- δ-, ζ- and η- class of carbonic anhydrases with amines and amino acids: a review.

Akocak S, Supuran CT.

J Enzyme Inhib Med Chem. 2019 Dec;34(1):1652-1659. doi: 10.1080/14756366.2019.1664501. Review.

50.

Synthesis and exploration of 2-morpholino-4-phenylthiazol-5-yl acrylamide derivatives for their effects against carbonic anhydrase I, II, IX and XII isoforms as a non-sulfonamide class of inhibitors.

Swain B, Singh Digwal C, Angeli A, Alvala M, Singh P, Supuran CT, Arifuddin M.

Bioorg Med Chem. 2019 Nov 1;27(21):115090. doi: 10.1016/j.bmc.2019.115090. Epub 2019 Sep 5.

PMID:
31515058

Supplemental Content

Loading ...
Support Center